The bidding window for Connplex Cinemas SME IPO was open from August 7, 2025, to August 11, 2025. The basis of allotment will be finalised today, August 12, 2025. Here’s how you can check the allotment status via NSE and Registrar.
Connplex Cinemas IPO is a book-building issue of ₹90.27 crores, consisting entirely of a fresh issue of 0.51 crore equity shares. The price band is set at ₹168 to ₹177 per share. The tentative listing date on NSE Emerge is August 14, 2025.
Beeline Capital Advisors Pvt.Ltd is the book-running lead manager, and MUFG Intime India Private Limited is the registrar for the issue.
The net proceeds from the fresh issue will be used to fund capital expenditure towards the following objectives:
Explore other Upcoming IPOs on BSE and NSE.
(August 11, 2025, end of the day)
Category |
Subscription (times) |
Qualified Institutional Investors (QIBs) |
44.21 |
Non-Institutional Investors |
49.75 |
Individual Investors (IND category bidding for 2 Lots) |
24.75 |
Total |
35.67 |
As of 12 August 2025, Connplex Cinemas IPO GMP stood at ₹13. The estimated listing price is ₹190, i.e., a 7.34% gain per share over the upper price band.
Source: Business Standard Report dated 12 August, 2025 Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market. |
Connplex Cinemas specialises in creating exceptional movie-going experiences through a well-integrated business model that spans theatre development, film exhibition and distribution, and diversified revenue-sharing avenues. Along with regular screenings, Connplex Cinemas hosts private screenings, corporate events, and community gatherings.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here